sorafenib has been researched along with nexavar in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (nexavar) | Trials (nexavar) | Recent Studies (post-2010) (nexavar) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 20 | 0 | 13 |
| Protein | Taxonomy | sorafenib (IC50) | nexavar (IC50) |
|---|---|---|---|
| melanocortin receptor 4 | Homo sapiens (human) | 4.48 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0143 | |
| Aurora kinase B | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
1 other study(ies) available for sorafenib and nexavar
| Article | Year |
|---|---|
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |